• $30.2 million in funding secured through underwriting agreement
• Pro forma cash balance of $63.7 million as at 30 September 2025
• Unprecedented interest in CT:VQ™, positioning CY26 as a transformational year

4DMedical Limited (ASX: 4DX) has announced that it has entered into an option underwriting agreement with Bell Potter Securities Limited to fully underwrite the exercise of the 4DXO listed options on issue, exercisable at $1.365 per option, and due to expire at 5:00pm AEDT on 31 December 2025. Approximately 22.2 million 4DXO options were originally issued, representing approximately $30.2 million in funds to 4DMedical if all were exercised. So far, approximately 8.0 million 4DXO options have been exercised, leaving 14.2 million unexercised options (Underwritten Options), representing an underwriting amount of approximately $19.25 million. Taking these funds into account, 4DMedical will have a pro forma cash balance as at 30 September 2025 of $63.7 million. The Underwriter will receive a cash fee of 2.5% of the Underwritten Amount. 4DMedical's CEO and Founder, Andreas Fouras, stated that 2025 has been an outstanding year for the company and its shareholders, and that this agreement ensures they have more than sufficient capital to execute their plans to commercialise CT:VQ™ and lead the company through to profitability. The company is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning 2026 as a transformational year.

4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning 2026 as a transformational year.